Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma

Published:2017-11-21 Issue:1 Volume:180 Page:60-70
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Cohen Alexa¹,Spektor Tanya M.¹,Stampleman Laura²,Bessudo Alberto³,Rosen Peter J.⁴,Klein Leonard M.⁵,Woliver Thomas⁶,Flam Marshall⁷,Eshaghian Shahrooz⁸,Nassir Youram⁹,Maluso Tina⁸,Swift Regina A.⁸,Vescio Robert¹⁰,Berenson James R.¹⁸¹¹^ORCID

Affiliation:

1. Oncotherapeutics; West Hollywood CA USA

2. Pacific Cancer Care; Monterey CA USA

3. California Cancer Associates for Research and Excellence; San Diego CA USA

4. Providence Saint Joseph Medical Center; Burbank CA USA

5. Illinois Cancer Specialists; Niles IL USA

6. Cancer Center of Santa Barbara; Santa Barbara CA USA

7. Hematology-Oncology Medical Group; Fresno CA USA

8. James R. Berenson, MD, Inc; West Hollywood CA USA

9. Cancer Care Institute; Los Angeles CA USA

10. Cedars-Sinai Medical Center; Los Angeles CA USA

11. Institute for Myeloma and Bone Cancer Research; West Hollywood CA USA

Funder

Celgene

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14992/fullpdf

Reference40 articles.

1. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy;Baz;Annals of Oncology,2006

2. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients;Berenson;British Journal of Haematology,2011

3. A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide for patients with relapsed/refractory multiple myeloma;Berenson;Leukemia,2012

4. Daratumumab single agent and daratumumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a real life retrospective evaluation;Branca;Blood,2016

5. A multicenter, open label phase I/II study of carfilzomib, pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (MM) patients;Bringhen;Blood,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposomal and Liposomes-Film Systems as Carriers for Bioactives from Paeonia tenuifolia L. Petals: Physicochemical Characterization and Biological Potential;Pharmaceutics;2023-12-07

2. Liposomal drug formulations for treatment of hematological malignancies;Expert Opinion on Pharmacotherapy;2023-10-17

3. Analysis of the effect of R-CHOP regimen of pegylated liposomal doxorubicin on elderly patients with stage III-IV diffuse large B-cell lymphoma;PAK J PHARM SCI;2021

4. Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety;Frontiers in Oncology;2021-03-25

5. Nanomedicine review: clinical developments in liposomal applications;Cancer Nanotechnology;2019-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3